Feng Biosciences

Clinical-stage therapeutics company that leverages its proprietary biomarker platform (XernaTM) to develop cancer drugs. XernaTM predicts the patients who are likely to benefit from a drug based on their biology and can improve the success of clinical trials by matching the right patient with the right treatment. The company’s lead program is Navicixizumab (Navi), a bispecific antibody targeting DLL4 and VEGF that has demonstrated single agent activity against multiple refractory solid cancers in two Phase 1 clinical trials.